4D Molecular Therapeutics, Inc. FDMT 深 滬
已收盤 06-18 16:00:00 美东时间
9.66
+0.240
+2.55%
華盛通- 最 高9.97
- 今 開9.72
- 成交量 89.22万股
- 最 低 9.45
- 昨 收 9.42
- 總市值 5.05亿
- 52周最高 12.34
- 市盈率 靜 --
- 換手率 1.71%
- 52周最低 3.68
- 委 比 -52.85%
- 總股本 5227.63万
- 歷史最高 55.11
- 量 比 1.11
- 振 幅 5.52%
- 歷史最低 2.235
- 每 手 1
- 風險率 2.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics granted 66,900 RSUs to seven new non-executive employees on June 9, 2026, under its 2025 Employment Inducement Award Plan. The Company, focused on advanced therapies for blinding retinal diseases and cystic fibrosis, has its lead product 4D-150 in Phase 3 for wet AMD and DME, and 4D-710 as the first gene therapy for CFTR delivery in cystic fibrosis. All products remain in clinical or preclinical development and are not F...
06-12 20:05
4DMT to Participate in Upcoming Investor Conferences
4DMT announced that its management will participate in investor conferences in June, presenting at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. The company is advancing therapeutic candidates targeting blinding retinal diseases and cystic fibrosis, with 4D-150 in Phase 3 for wet AMD and 4D-710 showing potential for CF treatment. Webcasts of the presentations will be...
05-27 12:00
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics granted 14 new non-executive employees 141,100 RSUs under its 2025 Employment Inducement Award Plan. The company is advancing innovative therapies with potential to transform treatment paradigms, including 4D-150 for retinal diseases and 4D-710 for cystic fibrosis. All product candidates are in clinical or preclinical development.
05-15 20:05
4D Molecular Therapeutics Q1 EPS $(1.01) Misses $(0.99) Estimate, Sales $3.047M Miss $5.167M Estimate
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.99) by 2.02 percent. This is a 17.44 percent decrease over losses of $(0.86) per
05-08 04:34
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics reported Q1 2026 financial results, highlighting strong execution in wet AMD trials and upcoming milestones. Enrollment in 4FRONT-1 Phase 3 was completed ahead of schedule, with topline data expected in H1 2027. 4FRONT-2 enrollment is expected to complete in H2 2026, with data in H2 2027. 2-year PRISM and SPECTRA data are anticipated in Q3 and H2 2026, respectively. The company has $458 million in cash to support operati...
05-07 20:05
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan March 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ferguson Enterprises, Hartford Insurance Group and JP Morgan, on Monday. HIGHLIGHT
03-30 15:35
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
